急性髓系白血病伴Inv(16)/t(16;16)的临床分析  

Clinical analysis of acute myeloid leukemia with inv(16)/t(16;16)

作　　者：李巍[1] 秘营昌[1] 王迎[1] 林冬[1] 魏辉[1] 刘旭萍[1] 李庆华[1] 王慧君[1] 卞寿庚[1] 王建祥[1] 

机构地区：[1]中国医学科学院北京协和医学院血液学研究所血液病医院,天津300020

出　　处：《临床血液学杂志》2010年第2期67-71,共5页Journal of Clinical Hematology

基　　金：863计划项目(No:2006AA02A405)

摘　　要：目的:探讨影响急性髓系白血病(AML)伴Inv(16)/t(16;16)患者临床特征、细胞遗传学特点以及生存、预后的主要因素。方法:对43例AML伴Inv(16)/t(16;16)患者进行总结分析、随访,了解一般情况、免疫分型、染色体核型及治疗、生存情况,对影响总体生存时间、无复发生存时间的因素进行统计学分析。结果:43例AML伴Inv(16)/t(16;16)患者总完全缓解(CR)率97.5%,1疗程CR率92.6%。所有患者的中位总生存时间(OS)未达(0.33～81.9个月),中位无复发生存(RFS)63.4(3.02～81.9)个月。3年OS率69%,5年OS率56%;3年RFS率68%,5年RFS率43%。统计学分析可见:≥45岁的患者与<45岁患者相比较OS、RFS期短,预后差。发病时一般特征、染色体核型及巩固治疗过程中采用中剂量Ara-C治疗的疗程数与OS无关。结论:年龄≥45岁是AML伴Inv(16)/t(16;16)的主要预后不良因素。Objective：To investigate the influence factors on survival and outcome of acute myeloid leukemia （AML） patients with inv（16）/t（16;16）.Method：Forty-three AML patients with inv（16）/t（16;16） after long-term follow-up were enrolled in the analysis of clinical feature,immunophenotype,chromosome karyotype and treatment regimen. The overall survival （OS） and replase-free survival （RFS） were statistically analyzed.Result：The overall CR rate of AML patients with inv（16）/（16;16） was 97.5%,CR rate after first course therapy was 92.6%.The median OS did not reach （0.33-81.9） months,median RFS was 63.4（3.02-81.9） months. The 3 years OS rate was 69% and 5 years OS rate was 56%. The 3 years RFS rate was 68% and 5 years RFS was 43%. Statistical analysis indicated that patients older than 45 years old had poorer prognosis,shorter OS and DFS than those younger than 45 years old.Conclusion：Advanced age （optimal cutpoint,45 years） was the major poor factor for AML with inv（16）/t（16;16）.

关 键 词：白血病 急性 染色体 治疗 预后 

分 类 号：R733.71[医药卫生—肿瘤]